ArticleJournal of microbiology and biotechnology2026
Development and Validation of an Enzyme-Linked Immunosorbent Assay for Measuring Factor XI in Intravenous Immunoglobulin Products by Mitigating Heterophilic Antibody Interference.
Article in Journal of microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thromboembolic events associated with intravenous immunoglobulin (IVIG) therapy have been linked to activated coagulation factor XI (FXIa). Therefore, regulatory authorities recommend monitoring FXI levels in IVIG products using quantitative assays, such as sandwich enzyme-linked immunosorbent assays (ELISAs). However, high concentrations of immunoglobulins in IVIG can cause heterophilic antibody interference, leading to false-positive FXI measurements. In this study, we aimed to develop and validate a sandwich ELISA capable of accurately measuring FXI while minimizing interference from high immunoglobin G (IgG) concentrations. We hypothesized that Purified human IgG (Fc) could serve as a heterophilic antibody blocker, thereby neutralizing non-specific interactions and improving assay reliability. The FXI measurements were compared with and without IgG blocker treatment across process intermediates and final IVIG products with varying IgG levels. False-positive signals were observed only in samples with high IgG concentrations and were eliminated after treatment with the IgG blocker. The modified ELISA demonstrated acceptable accuracy, precision, linearity, and quantification limits in accordance with the ICH Q2(R2) guidelines. This validated assay reliably quantified FXI regardless of IgG concentration, providing a robust platform for impurity assessment during IVIG manufacturing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.